Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 100 of 116 entries
View as:

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

Phase: N/A Priority: Normal
NCT ID: NCT04484818 Org: User:
Start: 03/01/21 End: 05/31/28 Due: 05/31/29

Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase: N/A Priority: Normal
NCT ID: NCT05721755 Org: User:
Start: 06/08/23 End: 03/31/30 Due: 03/31/31

Biomarkers in Patients With Head and Neck Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01466257 Org: User:
Start: 11/21/11 End: 01/01/12 Due: 01/01/13

Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting

Phase: N/A Priority: Normal
NCT ID: NCT03804255 Org: User:
Start: 01/08/19 End: 05/29/20 Due: 05/29/21

Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06084845 Org: User:
Start: 04/12/24 End: 05/31/28 Due: 05/31/29

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Phase: N/A Priority: Normal
NCT ID: NCT04266249 Org: User:
Start: 03/13/20 End: 12/31/38 Due: 12/31/39

FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00104884 Org: User:
Start: 10/04/05 End: 03/31/09 Due: 03/31/10

Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT03504644 Org: User:
Start: 08/03/18 End: 12/31/28 Due: 12/31/29

Comparing Two Methods to Follow Patients With Pancreatic Cysts

Phase: N/A Priority: Normal
NCT ID: NCT04239573 Org: User:
Start: 06/16/20 End: 06/03/37 Due: 06/03/38

Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

Phase: N/A Priority: Normal
NCT ID: NCT05710328 Org: User:
Start: 05/10/23 End: 12/31/29 Due: 12/31/30

Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement

Phase: N/A Priority: Normal
NCT ID: NCT04221438 Org: User:
Start: 09/22/21 End: 01/31/25 Due: 01/31/26

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

Phase: N/A Priority: Normal
NCT ID: NCT03267433 Org: User:
Start: 11/27/17 End: 01/31/27 Due: 01/31/28

Studying Tumor Samples From Women Who Have Undergone Chemotherapy for Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00897845 Org: User:
Start: 06/17/08 End: 12/02/13 Due: 12/02/14

Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study

Phase: N/A Priority: Normal
NCT ID: NCT05863351 Org: User:
Start: 09/07/23 End: 08/01/37 Due: 08/01/38

Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial

Phase: N/A Priority: Normal
NCT ID: NCT06319027 Org: User:
Start: 04/11/24 End: 05/31/27 Due: 05/31/28

To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring

Phase: N/A Priority: Normal
NCT ID: NCT04597359 Org: User:
Start: 10/05/21 End: 12/31/32 Due: 12/31/33

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT02445391 Org: User:
Start: 10/20/15 End: 03/29/31 Due: 03/29/32

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01863550 Org: User:
Start: 12/06/13 End: 02/05/34 Due: 02/05/35

Biomarkers of Response in Blood and Tumor Tissue Samples From Patients With Unresectable Stage IV Squamous Cell Cancer of the Head and Neck Previously Treated With Cetuximab, Cisplatin, and Radiation Therapy

Phase: N/A Priority: Normal
NCT ID: NCT01194635 Org: User:
Start: 08/05/10 End: 09/05/10 Due: 09/05/11

HER-2 Mutations in Tumor Samples From Patients With Advanced Non-Small Cell Lung Cancer Treated on Clinical Trial ECOG-2598

Phase: N/A Priority: Normal
NCT ID: NCT00896909 Org: User:
Start: 02/02/06 End: 07/02/06 Due: 07/02/07

Study of Tissue and Blood Samples From Patients With Recurrent Prostate Cancer Who Received Lapatinib on Clinical Trial ECOG-E5803

Phase: N/A Priority: Normal
NCT ID: NCT00897351 Org: User:
Start: 07/10/08 End: 02/10/09 Due: 02/10/10

Biomarkers in Patients With Diffuse Large B-Cell Lymphoma Treated With Combination Chemotherapy With or Without Rituximab

Phase: N/A Priority: Normal
NCT ID: NCT01131208 Org: User:
Start: 04/21/10 End: 08/21/10 Due: 08/21/11

Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT04527549 Org: User:
Start: 06/01/21 End: 01/08/24 Due: 01/08/25

Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery

Phase: N/A Priority: Normal
NCT ID: NCT02595424 Org: User:
Start: 04/06/16 End: 01/01/29 Due: 01/01/30

Analysis of Tumor Tissue and Lymph Nodes Surgically Removed From Patients With Cancers of the Head and Neck

Phase: N/A Priority: Normal
NCT ID: NCT00002695 Org: User:
Start: 04/30/96 End: 05/27/11 Due: 05/27/12